<DOC>
	<DOCNO>NCT02715882</DOCNO>
	<brief_summary>Randomized Single-blind Placebo-controlled Clinical Study Safety Tolerability CBLB502 Neo-adjuvant Treatment Patients With Colorectal Cancer , With Different Doses Regimens</brief_summary>
	<brief_title>Clinical Study Safety Tolerability CBLB502 Neo-adjuvant Treatment Patients With Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Written Patient Informed Consent participation study 2 . Men woman age 18 year 3 . Patients confirm diagnosis colorectal cancer , indication schedule surgery primary tumor removal 4 . Should previous anticancer therapy 5 . Patient 's life expectancy 3 month 6 . ECOG performance status 01 7 . Adequate hepatic renal function : Total bilirubin ≤1.5 upper limit normal ( ULN ) ) , Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 x ULN , regardless presence liver metastasis , Creatinine ≤2 x ULN 8 . Adequate cardiac function include : LVEF ≥45 echocardiogram ( ECHO ) multi gate acquisition scan , 12lead electrocardiogram ( ECG ) normal trace nonclinically significant change require medical intervention , QTcB interval QT ( QTc Bazett 's formula ) &lt; 470 msec history Torsades de Pointes symptomatic QTcB abnormality , Absence orthostatic hypotonia 9 . Negative test serological marker HIVinfection , viral hepatitis В С , syphilis 10 . Content use barrier contraception method male/female patient his/her partner study period 1 . Inability obtain write Informеd consent participation study 2 . History cardiovascular abnormality include condition state : Myocardial infarction/stroke last 6 month , Stable abnormality regional contractility , Cardiac failure ( NYHA functional class IIIIV ) , Confirmed cardiomyopathy , Clinically significant arrhythmias include condition state : QT prolongation syndrome , History II IIIdegree AVblock , Bradycardia ( HR &lt; 50 beat per min . ) tachycardia ( HR &gt; 100 beat per min . ) Blood pressure abnormality : 2 degree uncontrolled arterial hypertension ( systolic blood pressure &gt; 160 mm Hg diastolic blood pressure &gt; 105 mm Hg ) , Hypotension ( systolic blood pressure &lt; 90 mm Hg ) 3 . History severe allergic , systemic oncologic diseases 4 . Decompensated diabetes mellitus glycolated hemoglobin level ( HbA1c ) &gt; 7 % 5 . Administration drug product evident effect immune system previous 3 month prior screen ( include corticosteroid . Remark : Topical agent ( e.g . rash treatment ) , inhalation aerosol ( e.g . treatment bronchoobstructive disease ) , eye drop agent local administration ( e.g . joint cavity ) allow 6 . Participation clinical study administration study product 30 day prior screen , persist adverse reaction study product 7 . Patients take CBLB502 8 . Patients hypersensitivity/allergy CBLB502 excipients drug product ; NSAID ( include ibuprofen ) 9 . Pregnant lactate woman 10 . History salmonellosis 11 . Body mass &gt; 88 kg ; obesity mean BMI range 18.525 kg/m2 woman 2227 kg/m2 men 12 . Men woman childbearing age agree use double contraception method , oral contraception abstain sex contact throughout study 13 . Alcohol abuse , drug abuse medical , psychological social reason may , accordance investigator , affect patient 's participation study , may prevent adequate assessment study result 14 . Any condition unstable may endanger patient 's safety and/or affect his/her adherence investigator instruction 15 . Any patient able willing cooperate investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>TLR5</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>